Gastrointestinal (G1) Cancer Trials
Current Trials and Studies GI429: ROSETTA Gastric-204: A Blinded, Randomized, Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus […]
Current Trials and Studies GI429: ROSETTA Gastric-204: A Blinded, Randomized, Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus […]
Current Trials and Studies BRE437: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+,
Lung Cancer Current Open Trials and Studies LUN 567: An Open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination)
Missouri Cancer Associates offers Low-Dose Radiation Therapy (LDRT)—a safe, non-invasive treatment option for patients suffering from painful osteoarthritis who are
Help Advance a Potential Targeted Treatment for PD-L1–Positive Non-Small Cell Lung Cancer Cancer cells can use a variety of strategies
Clinical Trial Details Study Name: ALISCA™-Breast1(BRE437) Type: Phase 2 study of alisertib (investigational drug) with endocrine therapy Patients: HR+, HER2-negative
A Study for Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) We are currently enrolling participants for the TIGOS-LS clinical trial,
Welcome to Missouri Cancer Associates. This video is designed to help you understand what to expect as you start your
The possibility of hair loss or changes during cancer treatment can be distressing for many patients. Understanding what to expect
Receiving a cancer diagnosis can feel overwhelming for both patients and their families. Increased anxiety or distress is normal, and
Cancer treatments can cause various changes to your skin and nails, including increased sensitivity, rashes, and other skin conditions. It’s
When you come for treatment at Missouri Cancer Associates, your care team will often draw a blood sample to monitor